Rna Diagnostics Inc.

We are dedicated to improving cancer therapy management. RDA™ is a cancer diagnostic platform measuring tumor response early in treatment.

[Gisele Roberts @GiseleRoberts1]

As we near the 10 year anniversary of the creation of @RnaDiagnostics, here's an outstanding description of the technology behind the discovery by @LaurentianU prof Amadeo Parissenti that saves lives, improves cancer patient outcomes and lowers treatment costs. #cdninnovation

[MEDTEQ+ @MEDTEQ_CA]

After a quick presentation of our tools, @aifredhealth and @jbridgecook from @RnaDiagnostics will present the challenges they faced and how MEDTEQ helped them overcoming those challenges. Cc @JCaudroit and @Iris__LEROUX

[Gisele Roberts @GiseleRoberts1]

Whether partnering with @hard_lineglobal to create effective learning environments for students or
@RnaDiagnostics to improve patient outcomes, @LaurentianU is committed to building a sustainable and innovative economy with its local community @OntUniv https://t.co/IIF6hYBxNc

[Rna Diagnostics Inc. @RnaDiagnostics]

President/CEO Jeremy Bridge-Cook explains how RNA Disruption Assay (RDA) will impact #breastcancer treatment in future. BREVITY is Rna Diagnostics’ current international breast cancer clinical trial for validation of RDA. Visit website in bio @bccww https://t.co/yrMU4u5EWK

[Rna Diagnostics Inc. @RnaDiagnostics]

President/CEO Jeremy Bridge-Cook explains how RNA Disruption Assay (RDA) will impact #breastcancer treatment in future. BREVITY is Rna Diagnostics’ current international breast cancer clinical trial for validation of RDA. @NORCAT @startupnorth https://t.co/yrMU4u5EWK

[Rna Diagnostics Inc. @RnaDiagnostics]

President/CEO Jeremy Bridge-Cook explains how RNA Disruption Assay (RDA) will impact #breastcancer treatment in future. BREVITY is Rna Diagnostics’ current international breast cancer clinical trial for validation of RDA. @LifeSciencesON @OCEinnovation https://t.co/yrMU4u5EWK

[Rna Diagnostics Inc. @RnaDiagnostics]

President/CEO Jeremy Bridge-Cook explains how RNA Disruption Assay will impact #breastcancer treatment in future. BREVITY is Rna Diagnostics’ current international #breastcancer clinical trial for validation of RDA. @GiseleRoberts1 @LaurentianU @HSNRI https://t.co/yrMU4u5EWK

[Rna Diagnostics Inc. @RnaDiagnostics]

President/CEO Jeremy Bridge-Cook explains how RNA Disruption Assay (RDA) will impact #breastcancer treatment in future. BREVITY is Rna Diagnostics’ current international breast cancer clinical trial for validation of RDA.
@Startup_Canada @startuphereTO https://t.co/yrMU4u5EWK

[Rna Diagnostics Inc. @RnaDiagnostics]

President/CEO Jeremy Bridge-Cook explains how RNA Disruption Assay (RDA) test will impact #breastcancer treatment in future. BREVITY is the current international #breastcancer clinical trial for validation of RDA.
For more info visit the website in bio https://t.co/yrMU4u5EWK

[Health Sciences North / Horizon Santé-Nord @HSN_Sudbury]

BREVITY is open and accruing patients! Learn more about how a partnership w/ @HSNRI @RNADiagnostics @LaurentianU and HSN Physicians is helping breast cancer patients. https://t.co/HBs4NZmcog

Plus de renseignements ici! https://t.co/lCma5TgVSI

[HSNRI @HSNRI]

Dr Amadeo Parissenti took part in #IGS2018 round table on the #medtech sector in #NorthernOntario. Discussing his success with @RnaDiagnostics and the Brevity trial.

[Mike Commito @mikecommito]

Innovation for a Greater Sudbury was a rousing success last night. Some great insights from @JeremyLaurinOCE, @MetricAid, @RnaDiagnostics, Verv Technologies and Madiha Khan, our moderator. Thanks to everyone who joined us. The future of MedTech in northern Ontario is bright

[NORCAT @NORCAT]

Dr Amadeo Parissenti, Chief Scientific Officer of @RnaDiagnostics, believes it is important for Northern Ontario to innovate in the medtech sector to provide more efficient, personalized, and cost efficient healthcare for the aging population. #IGS2018

[NORCAT @NORCAT]

Holding a PhD in biochem from @yorkuniversity & medicine fellowships from @Harvard and @uoftmedicine, Dr. Amadeo Parissenti, Chief Scientific Officer of @RnaDiagnostics and @LaurentianU professor is an authority on drug resistance in breast & ovarian cancer.

[Mike Commito @mikecommito]

Innovation for a Greater Sudbury: The Future of MedTech is happening this Thursday evening. Our keynote speaker is @JeremyLaurinOCE, followed by a local roundtable that includes @RnaDiagnostics, @MetricAid and Verv Technologies. RSVP: https://t.co/Bqw211HTw3

[Rna Diagnostics Inc. @RnaDiagnostics]

Rna Diagnostics Inc., a #Canadian company with a patented platform #technology providing real-time #cancer therapy guidance, announced today the closing of a $5 million Series A financing. https://t.co/Umtg2vE06N @tweissenburger

[Rna Diagnostics Inc. @RnaDiagnostics]

Rna Diagnostics Inc., a #Canadian company with a patented platform #technology providing real-time #cancer therapy guidance, announced today the closing of a $5 million Series A financing. https://t.co/Umtg2vE06N @TradeON @CanadaTrade

[Rna Diagnostics Inc. @RnaDiagnostics]

Rna Diagnostics Inc., a #Canadian company with a patented platform #technology providing real-time #cancer therapy guidance, announced today the closing of a $5 million Series A financing https://t.co/Umtg2vE06N @OCEinnovation @ONeconomy @EcoDevGTA

[Rna Diagnostics Inc. @RnaDiagnostics]

Rna Diagnostics Inc., a #Canadian company with a patented platform #technology providing real-time #cancer therapy guidance, announced today the closing of a $5 million Series A financing https://t.co/Umtg2vE06N @ScienceMin @OntInnovation

[Rna Diagnostics Inc. @RnaDiagnostics]

Rna Diagnostics Announces $5M Series A Financing Round Led by iGAN Partners https://t.co/Umtg2vE06N @CanInnovation @CBCCanada